Cipla's Sanjay Joseph ceases to be Senior Managerial Personnel

Cipla Limited has announced that Mr. Sanjay Joseph, Head – API Business, will cease to be Senior Managerial Personnel (SMP) effective July 24, 2026. This decision results from a change in his reporting structure, as approved by the Board of Directors during its meeting on July 23, 2026.

The Board meeting, which commenced at 9:15 a.m. IST, concluded at 13:00 p.m. IST on the same day. The company stated that the necessary details regarding this change have been provided in Annexure A of the regulatory filing.

Details of the Change

The transition is categorized under a change in reporting rather than a resignation, removal, or death. The specific term of employment and brief profile were not disclosed as they were deemed not applicable to this specific cessation.

Particulars	Details
Name	Mr Sanjay Joseph
Designation	Head – API Business
Reason for change	Change in reporting structure
Effective date of cessation	July 24, 2026

The disclosure was submitted to BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.60%	-1.83%	+1.63%	+8.90%	-7.11%	+62.12%

Cipla and Dr. Reddy's are among the Indian pharmaceutical firms positioned to benefit from the emerging GLP-1 opportunity in the domestic market, according to a Financial Express report. The growing interest in GLP-1 class drugs, which are used in the treatment of diabetes and obesity, is expected to provide a meaningful boost to the domestic business of these companies.

Semaglutide Patent Expiry Opens New Doors

A key development supporting this opportunity is the expiry of semaglutide's patent in the domestic market in March. This patent expiry has allowed Indian pharmaceutical companies to enter the semaglutide segment, enabling them to launch generic versions of the drug and compete in a space that was previously restricted.

Parameter:	Details
Drug Class:	GLP-1
Key Molecule:	Semaglutide
Patent Expiry (Domestic Market):	March
Companies Referenced:	Cipla, Dr. Reddy's
Source:	Financial Express

Domestic Business Outlook

The GLP-1 segment represents a significant growth avenue for Indian pharma companies in the domestic formulations market. With semaglutide's patent now expired domestically, companies like Cipla and Dr. Reddy's have the opportunity to capture a share of this rapidly growing therapeutic category. The development is seen as a positive catalyst for the domestic business of these pharmaceutical firms, as demand for GLP-1 drugs continues to rise in India.